BioSpace News Archive

The global actinic keratosis treatment market size is expected to be worth around US$ 10.12 billion by 2030, according to a new report by Vision Research Reports.

According to Nova one advisor, the global Microbiome Therapeutics market was valued at USD 100.4 million in 2021 and it is expected to hit around USD 973.75 million by 2030 with a CAGR of 31.40% during the forecast period 2022 to 2030.

GoodCap Pharmaceuticals Inc. (“GoodCap” or the “Company”), a biopharmaceutical company developing low-dose psychedelic therapies, is pleased to announce that the Natural Sciences and Engineering Research Council of Canada (NSERC) has awarded an Alliance Grant to its research partner at the University of Toronto (the “University”) for $237,339, effective October 2022 to be paid through 2023.

Todos Medical, Ltd., a comprehensive medical diagnostics and related solutions company, announced that it has terminated the Tollovid™ products license and distribution agreement it had with T-Cell Protect Hellas S.A.

After the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by the European Commission, as a booster for the prevention of COVID-19 in adults 18 years of age and older.

OMass Therapeutics, a biotechnology company that identifies medicines against highly validated target ecosystems, highlights the potential benefits of native mass spectrometry in drug discovery through its new publication “Mass spectrometry captures biased signalling and allosteric modulation of the β1 adrenergic receptor” published today in Nature Chemistry1.

The nearly 200-year-old phrase “you are what you eat” has some new evidence. ISB researchers have found that the gut microbiome, including what we feed it, is largely responsible for the variation in circulating blood metabolites across people.

IQVIA™ announced a long-term collaboration with Clalit, the largest health services organization in Israel, to launch the first Prime Site in the country.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”) today announces compelling new clinical data from the TACTI-002 all-comer PD-L1 Phase II trial evaluating Immutep’s lead product candidate, eftilagimod alpha (“efti” or “IMP321”) in combination with MSD’s (Merck & Co., Inc., Rahway, NJ., USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in 114 patients with 1L NSCLC.

PACT Pharma, Inc. today reported data from the first clinical study using CRISPR gene editing technology to substitute a gene in patients’ immune cells to treat cancer.